Merck & Co. Inc.'s FDA clearance, almost two months earlier than expected, of PD-1-targeting Keytruda (pembrolizumab) for melanoma holds the title for gaining the first U.S. approval of a drug in the class, but restrictions in the label have meant "a lot of head-scratching," said Robert Pierce, formerly director of Merck's anti-PD-1 development team.